The poster "Effectiveness and safety of ixazomib-based therapy in relapsed/refractory multiple myeloma outside of a clinical trial: Final analysis of the 'Use Via Early Access to Ixazomid' (UVEA-IXA) study" was presented at the Congress of European Hematology Association (EHA), June 9-17 2021
